Amgen Inc. Stock
€251.80
Your prediction
Amgen Inc. Stock
Pros and Cons of Amgen Inc. in the next few years
Pros
Cons
Performance of Amgen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 2.150% | 3.181% | -2.781% | -14.868% | -1.616% | 4.738% | 8.758% |
| Exact Sciences | -0.680% | 5.048% | -8.615% | 17.139% | -14.849% | 17.406% | -40.451% |
| Regeneron Pharmaceuticals Inc. | 2.380% | 0.935% | 4.903% | -53.921% | -32.939% | -20.547% | -16.202% |
| Incyte Corp. | -0.140% | -1.884% | 1.851% | 2.857% | -11.260% | -21.697% | -36.102% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.
Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.
Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.
Comments
News
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the
Why Amgen Stock Popped by 4% Today
Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4%
2 Dividend Stocks to Buy on the Dip and Hold Forever
Over the past year, Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds. Apple is